Choice of vincristine or 6-mercaptopurine on the basis of polyamine level in tumor-bearing regions of the brain

Cancer Letters

Volumn 139, Issue 1, 1999, Pages 51-58

  Watanabe, Satoru ^a   Sato, Shoichi ^b   Nagase, Sumika ^b   Shimosato, Kazuaki ^a   Ohkuma, Seitaro ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b Kawasaki College of Allied Health Professions   (Japan)

Author keywords

6 Mercaptopurine; Brain cancer; Polyamine; Vincristine

Indexed keywords

MERCAPTOPURINE; POLYAMINE; SPERMIDINE; SPERMINE; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN CANCER; BRAIN CORTEX; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DIENCEPHALON; DRUG CHOICE; DRUG EFFECT; HIPPOCAMPUS; HYPOTHALAMUS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR GROWTH;

6-MERCAPTOPURINE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MALE; POLYAMINES; PUTRESCINE; RATS; RATS, SPRAGUE-DAWLEY; SPERMIDINE; SPERMINE; VINCRISTINE;

EID: 0032924307     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00012-9     Document Type: Article

References (33)

1. Sunkara P.S., Fowler S.K., Nishioka K. Inhibition of polyamine biosynthesis by α-difluoromethyl ornithine potentiates the cytotoxic effects of arabinosyl cytosine in Hela cells. Biochem. Biophys Res. Comm. 95:1980;423-430.
2. Sunkara P.S., Fowler S.K., Nishioka K. Selective killing of transformed cells in combination with inhibitors of polyamine biosynthesis and e-phase specific drugs. Cell Biol. Int. Rep. 5:1981;991-997.
3. Bartholeyns J., Weser J.K. Effects of α-difluoromethylornithine alone and combined with adriamycin or vindesine on L1210 leukemia in mice. EMT6 solid tumors in mice and solid tumors induced by injection of hepatoma tissue culture cells in rats, Cancer Res. 41:1981;5158-5161.
4. Quemener V., Moulinoux J.P., Havouis R., Seiler N. Polyamine deprivation enhances anti umoral efficacy of chemotherapy. Anticancer Res. 12:1992;1447-1454.
5. Quemener V., Blanchard Y., Chamaillard L., Havouis R., Cipolla B., Moulinoux J.P. Polyamine deprivation: a new tool in cancel treatment. Anticancer Res. 14:1994;443-448.
6. Cipolla B., Blanchard Y., Chamaillard L., Quemener V., Guille F., Ilavouis R., Moulinoux J.P. In vivo, synergistic inhibition of MAT-LyLU rat prostatic adenocarcinoma growth by polyamine deprivation and low-dose cyclophosphamide, Urol. Res. 24:1996;93-98.
7. Watanabe S., Sato S., Nagase S., Saito T. novel note on the effect of ara-C on the polyamine content of the male accessory organs of the rat. Biochem. Pharmarcol. 44:1992;593-596.
8. Watanabe S., Sato S., Nagase S., Saito T. Polyamine increase in rats tissues treated with ara-C and 5-FU. Anti-Cancer Drugs. 4:1993;345-350.
9. Watanabe S., Sato S., Nagase S., Saito T. Therapeutic significance of the polyamine level in tissues of rats treated with adriamycin and cisplatin. Anti-Cancer Drugs. 7:1996;114-120.
10. Tofilon P.J., Deen D.F., Marton L.J. α-Difluoromethylornithine-induced polyamine depletion of 9L tumor cells modifies drug-induced DNA cross-link formation. Science. 222:1981;1132-1135.
11. Tofilon P.J., Deen D.F., Marton L.J. Polyamine depletion and drug-induced chromosomal damage: new results. Science. 258:1992;1378.
12. Hongisto L.A., Hung D.T., Deen D.F., Marton L.J. Decreased cell kill of vincristine and methotrexate against 6L rat brain tumor cells in vitro caused by α-difluoromethylornithine-induced polyamine depletion. Cancer Res. 44:1984;4440-4442.
13. Oredsson S.M., Gray J.W., Deen D.F., Marton L.J. Decreased cytotoxicity of 1-β-D-arabinofuranosylcytosine in 9L rat brain tumor cells pretreated with α-difluoromethylornithine in vitro. Cancer Res. 43:1983;2541-2544.
14. Sunkara P.S., Rosenberger A.L. Antimetastatic activity of DL-α-difluoromethylornithine, an inhibitor of polyamine biosynthesis, in mice, Cancer Res. 47:1987;933-935.
15. Watanabe S., Sato S., Nagase S., Tomita M., Saito T., Ishizu H. Automated quantitation of polyamines by improved cation-exchange high-performance liquid chromatography using a pump equipped with a plunger washing system. J. Liquid Chromatogr. 16:1992;619-632.
16. Seiler N., Knodgen B. High-performance liquid chromatographic procedure for the simultaneous determination of the natural polyamines and their monoacetyl derivatives. J. Chromatogr. 971:1980;227-236.
17. Marton L.J., Pegg A.E. Polyamines as targets for therapeutic intervention. Ann. Rev. Pharmacol. Rev. 35:1995;55-91.
18. Janne J., Alhonen L., Leinonen P. Polyamines: from molecular biology to clinical applications. Ann. Med. 23:1991;241-259.
19. Ernestus R.I., Rohn G., Hossomann K.A., Paschen W. Polyamine metabolism in experimental brain tumors of rat. J. Neurochem. 6:1993;417-422.
20. Greig N.H., Soncrant T.T., Shetty H.U., Momma S., Smith Q.R., Rapoport S.I. Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat. Cancer Chemother. Pharmacol. 26:1990;263-268.
21. Begley D.J. The interaction of some centrally active drugs with the blood-brain barter and circumventricular organs. Prog. Brain Res. 91:1997;163 - 169.
22. Roelcke U. Brain tumor biochemistry. J. Neuro-oncol. 2:1994;275-279.
23. Muzylak M., Maslinska D. Neurotoxic effect of vincristine or ultrastructure of hypothalamus in rabbits. Folia. Hist. Cytobiol. 30:1997;113-118.
24. Tomita K., Hazama F., Mikawa H. Neurotoxicity of vincristine after the osmotic opening of the blood-brain barrier. Neuropath. Appl. Neurobiol. 9:1983;345-354.
25. Rosenthal S., Kaufman S. Vincristine neurotoxicity. Neurol. (Minneap.). 19:1974;367-369.
26. Singh L., Oles R., Woodruff G. Invitro interaction of a polyamine with the NMDA receptor. Eur. J. Pharmacol. 180:1990;391-392.
27. Heston W.D.W., Kadmon D., Lazan D.W., Fair W.R. Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor difluoromethylornithine. Prostate. 3:1984;383-389.
28. Coleman C.S., Wallace H.M. Polyamine excretion from human cancer cells. Biochem. Soc. Trans. 1990;1228-1229.
29. Friedman L., Gaines D.W., Alleva F.R., Seidler F.J., Flynn T.L., Slotkin T.A., Balazs T. Macromolecular levels. DNA synthesis and ornithine decerboxylase activity in leg muscles from. 6:1986;57-68.
30. Osswald H., Herrmann R., Jones G.R.N., Kitta D., Kunz W. Urinary polyamine excretion by tumor-bearing and tumor-free mice exposed to cyclophosphamide. 5-fluorouracil and 6-mercaptopurine, J. Cancer Res. Clin. Oncol. 111:1986;141-148.
31. Elfarra A.A., Hwang I.Y. Targeting of 6-mercaptopurine to the kidneys: metabolism and kidney-selectivity of s-(6-purinyl)-L-cysteine analogs in rats. Drug Metab. Dispos. 21:1993;841-845.
32. Matsumura S., Hoshino T., Weizsnecker M., Deen D.F. Paradoxical behavior of 6-mercaptopurine as a cytotoxic agent: decreasing cell kill with increasing drug dose. Cancer Treat. Res. 67:1983;475-480.
33. Shipe J.R., Savoty J., Wilis M.R. Polyamines as tumor markers. Crit. Rev. Clin. Lab. Sci. 16:1981;1-34.